871 - Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)

Presenting Author(s)

• 

  George R. Thompson, III, MD

  Professor
  University of California Davis Medical Center
  Sacramento, California, United States

  Disclosure: Disclosure(s): Amplyx: Advisor/Consultant (), Grant/Research Support (); Astellas: Advisor/Consultant (), Grant/Research Support (); Cidara: Advisor/Consultant (), Grant/Research Support (); F2G: Advisor/Consultant (), Grant/Research Support (); Merck: Grant/Research Support (); Pfizer: DSMB (); Scynexis: Advisor/Consultant (), Grant/Research Support ()

Co-Author(s)

• TK

  Thomas King, MS MPH

  SCYNEXIS, Inc.
  Jersey City, New Jersey, United States

  Disclosure: Disclosure(s): SCYNEXIS, Inc.: employee (), Stocks/Bonds ()
• 

  Nkechi Azie, MD MBA FIDSA

  VP, Clinical Development
  SCYNEXIS, Inc.
  Jersey City, NJ, United States

  Disclosure: Disclosure(s): SCYNEXIS, Inc.: employee (), Stocks/Bonds ()
• DA

  David A. Angulo, MD

  Chief Medical Officer
  SCYNEXIS, Inc.
  Jersey City, New Jersey, United States

  Disclosure: Disclosure(s): SCYNEXIS, Inc.: employee (), Stocks/Bonds ()
• JP

  Juergen Prattes, MD, FECMM

  Physician
  Medical University of Graz
  Graz, Steiermark, Austria

  Disclosure: Disclosure(s): No financial relationships to disclose